680 related articles for article (PubMed ID: 10101019)
1. Cox-2-selective inhibitors: the new super aspirins.
DeWitt DL
Mol Pharmacol; 1999 Apr; 55(4):625-31. PubMed ID: 10101019
[No Abstract] [Full Text] [Related]
2. COX-2 inhibitors--is there cause for concern?
Seibert K; Lefkowith J; Tripp C; Isakson P; Needleman P
Nat Med; 1999 Jun; 5(6):621-2. PubMed ID: 10371498
[No Abstract] [Full Text] [Related]
3. The future of NSAID therapy: selective COX-2 inhibitors.
Vane JR; Botting RM
Int J Clin Pract; 2000; 54(1):7-9. PubMed ID: 10750251
[No Abstract] [Full Text] [Related]
4. [COX-1 and COX-2: functions and pharmacological effects].
Hinz B; Brune K
Pharm Unserer Zeit; 1999 Jan; 28(1):21-9. PubMed ID: 10078026
[No Abstract] [Full Text] [Related]
5. The development of COX2 inhibitors.
Flower RJ
Nat Rev Drug Discov; 2003 Mar; 2(3):179-91. PubMed ID: 12612644
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of cyclooxygenase (COX) enzymes by compounds from Daucus carota L. Seeds.
Momin RA; De Witt DL; Nair MG
Phytother Res; 2003 Sep; 17(8):976-9. PubMed ID: 13680840
[TBL] [Abstract][Full Text] [Related]
7. [New NSAIDS: COX-1, COX-2, what about them?].
Peretz A
Rev Med Brux; 1998 Sep; 19(4):A399-402. PubMed ID: 9805982
[TBL] [Abstract][Full Text] [Related]
8. Building a better aspirin.
Pennisi E
Science; 1998 May; 280(5367):1191-2. PubMed ID: 9634399
[No Abstract] [Full Text] [Related]
9. [How do aspirin and company work? Cyclooxygenases--point of attack of nonsteroidal antirheumatics].
Steinhilber D
Pharm Unserer Zeit; 2002; 31(2):140-4. PubMed ID: 11977449
[No Abstract] [Full Text] [Related]
10. [What's in the future? New NSAIDs].
Laufer S
Pharm Unserer Zeit; 2002; 31(2):164-9. PubMed ID: 11977452
[No Abstract] [Full Text] [Related]
11. COX-1 and COX-2 inhibition: current status and future perspective.
Greyn J; Lauwers MH; Vanlersberghe C; Camu F
Acta Anaesthesiol Belg; 1998; 49(3):175-83. PubMed ID: 9844704
[No Abstract] [Full Text] [Related]
12. New perspectives for nonsteroidal antiinflammatory therapy.
de Brum-Fernandes AJ
J Rheumatol; 1997 Feb; 24(2):246-8. PubMed ID: 9034978
[No Abstract] [Full Text] [Related]
13. The discovery and function of COX-2.
Needleman P; Isakson PC
J Rheumatol Suppl; 1997 Jul; 49():6-8. PubMed ID: 9249644
[No Abstract] [Full Text] [Related]
14. Inducible cyclooxygenase may have anti-inflammatory properties.
Gilroy DW; Colville-Nash PR; Willis D; Chivers J; Paul-Clark MJ; Willoughby DA
Nat Med; 1999 Jun; 5(6):698-701. PubMed ID: 10371510
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and biological evaluation of N-acetyl-2-(or 3-)carboxymethylbenzenesulfonamides as cyclooxygenase isozyme inhibitors.
Chen QH; Rao PN; Knaus EE
Bioorg Med Chem; 2005 Aug; 13(15):4694-703. PubMed ID: 15914011
[TBL] [Abstract][Full Text] [Related]
16. Quantitative structure activity relationship studies of diaryl furanones as selective COX-2 inhibitors.
Shahapurkar S; Pandya T; Kawathekar N; Chaturvedi SC
Eur J Med Chem; 2004 Apr; 39(4):383-8. PubMed ID: 15072847
[TBL] [Abstract][Full Text] [Related]
17. Cyclooxygenase-3 (COX-3): filling in the gaps toward a COX continuum?
Warner TD; Mitchell JA
Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13371-3. PubMed ID: 12374850
[No Abstract] [Full Text] [Related]
18. Covalent modification of cyclooxygenase-2 (COX-2) by 2-acetoxyphenyl alkyl sulfides, a new class of selective COX-2 inactivators.
Kalgutkar AS; Kozak KR; Crews BC; Hochgesang GP; Marnett LJ
J Med Chem; 1998 Nov; 41(24):4800-18. PubMed ID: 9822550
[TBL] [Abstract][Full Text] [Related]
19. New cyclooxygenase-2/5-lipoxygenase inhibitors. 3. 7-tert-butyl-2, 3-dihydro-3,3-dimethylbenzofuran derivatives as gastrointestinal safe antiinflammatory and analgesic agents: variations at the 5 position.
Janusz JM; Young PA; Ridgeway JM; Scherz MW; Enzweiler K; Wu LI; Gan L; Chen J; Kellstein DE; Green SA; Tulich JL; Rosario-Jansen T; Magrisso IJ; Wehmeyer KR; Kuhlenbeck DL; Eichhold TH; Dobson RL
J Med Chem; 1998 Aug; 41(18):3515-29. PubMed ID: 9719605
[TBL] [Abstract][Full Text] [Related]
20. Aspirin, but not NO-releasing aspirin (NCX-4016), interacts with selective COX-2 inhibitors to aggravate gastric damage and inflammation.
Wallace JL; Zamuner SR; McKnight W; Dicay M; Mencarelli A; del Soldato P; Fiorucci S
Am J Physiol Gastrointest Liver Physiol; 2004 Jan; 286(1):G76-81. PubMed ID: 14665439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
